Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Core Insights - Nurix Therapeutics is advancing its clinical development plans for bexobrutideg, targeting relapsed/refractory chronic lymphocytic leukemia (CLL) with pivotal trials set to begin in the second half of 2025 [1][2] - The company reported a cash position of $428.8 million as of August 31, 2025, indicating strong capitalization for ongoing and future projects [1][8] Clinical Development - Bexobrutideg is set to undergo a single-arm study for potential accelerated approval in relapsed/refractory CLL patients, alongside a randomized controlled Phase 3 trial [2] - Preclinical data for GS-6791, an IRAK4 degrader developed in collaboration with Gilead, demonstrated significant efficacy in a dermatitis model, showcasing its potential in autoimmune diseases [1][2] - Recent Phase 1a data for bexobrutideg in CLL showed an overall response rate (ORR) of 80.9% among 47 evaluable patients, with rapid responses and durable activity noted [2][3] Financial Performance - Revenue for the fiscal quarter ended August 31, 2025, was $7.9 million, a decrease from $12.6 million in the same quarter of 2024, primarily due to the conclusion of the initial research term with Sanofi [4] - Research and development expenses increased to $86.1 million from $55.5 million year-over-year, reflecting accelerated clinical activities [5] - The net loss for the quarter was $86.4 million, or $1.03 per share, compared to a net loss of $49.0 million, or $0.67 per share, in the prior year [6] Pipeline and Collaborations - Nurix is also advancing other drug candidates, including Zelebrudomide for B-cell malignancies and NX-1607 for immuno-oncology indications, with ongoing clinical trials [7] - The company maintains strategic collaborations with Gilead, Sanofi, and Pfizer, focusing on various degrader programs and anticipating further updates throughout 2025 [7]